This Article Full Text Full Text (PDF) Supplementary Material Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Komatsu, M. Articles by Nishiyama, M. Search for Related Content PubMed PubMed Citation Articles by Komatsu, M. Articles by Nishiyama, M.

Departments of ¹ Translational Cancer Research and ² Environmetrics and Biometrics, Research Institute for Radiation Biology and Medicine, ³ Natural Science Center for Basic Research and Development, ⁴ Department of Obstetrics and Gynecology, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan; ⁵ Department of Obstetrics and Gynecology, Tottori Medical School, Tottori, Japan; and ⁶ Department of Obstetrics and Gynecology, Jichi Medical School, Tochigi, Japan

Requests for reprints: Masahiko Nishiyama, Department of Translational Cancer Research, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8553, Japan. Phone: 81-82-257-5839; Fax: 81-82-256-7105. E-mail: yamacho{at}hiroshima-u.ac.jp

We attempted to identify potent marker genes using a new statistical analysis and developed a prediction system for individual response to platinum/paclitaxel combination chemotherapy in ovarian cancer patients based on the hypothesis that expression analysis of a set of the key drug sensitivity genes for platinum and paclitaxel could allow us to predict therapeutic response to the combination. From 10 human ovarian cancer cell lines, genes correlative in the expression levels with cytotoxicities of cisplatin (CDDP) and paclitaxel were chosen. We first selected five reliable prediction markers for the two drugs from 22 genes already known as sensitivity determinants and then identified another 8 novel genes through a two-dimensional mixed normal model using oligomicroarray expression data. Using expression data of genes quantified by real-time reverse transcription-PCR, we fixed the best linear model, which converted the quantified expression data into an IC₅₀ of each drug. Multiple regression analysis of the selected genes yielded three prediction formulae for in vitro activity of CDDP and paclitaxel. In the same way, using the same genes selected in vitro, we then attempted to develop prediction formulae for progression-free survival to the platinum/paclitaxel combination. We therefore constructed possible formulae using different sets of 13 selected marker genes (5 known and 8 novel genes): Utility confirmation analyses using another nine test samples seemed to show that the formulae using a set of 8 novel marker genes alone could accurately predict progression-free survival (r = 0.683; P = 0.042). [Mol Cancer Ther 2006;5(3):767–75]

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

⁷ http://www.ncbi.nlm.nih.gov.geo/.

⁸ http://apollo.rbm.hiroshima-u.ac.jp/.

⁹ Supplementary material for this article is available at Molecular Cancer Therapeutics online (http://aacrjournals.org/).

Received 10/ 6/05; revised 1/ 6/06; accepted 1/18/06.